TABLE 2.

Environmental consideration of guidance

Environmental policy	CCGs using policy—No. (%)
Explicit statement of preference	For MDIs	None stated	For DPIs
	17/144 (12)	122/144 (85)	5/144 (3)
Presence of Ventolin MDI	34/130 (26)
Presence of HFA 227ea MDIs	83/142 (58)
Low‐dose ICS: Option of 2 puffs bi‐daily	126/134 (94)
Recommendation about disposal (either returning to pharmacy, incineration, or recycling)	0/144 (0)

Column 1 lists 5 potential features on a guidance document relating to greenhouse emissions. For each feature column 2 states the number and percentage of CCGs that used a guidance document containing that feature in 2019. Denominators vary as not every document contained adequate information to answer this question. For example, some documents did not contain any mention of short‐acting β‐agonist inhalers, so information on Ventolin could not be collected. The difference in denominators between this table and Table 2 is explained in full detail in Appendix 4.

CCG, clinical commissioning group; ICS, inhaled corticosteroid; MDI, metered‐dose inhaler; DPI, dry powder inhaler.